We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
VectorBuilder and Landau To Establish World’s First Primate Gene Therapy R&D Center
Product News

VectorBuilder and Landau To Establish World’s First Primate Gene Therapy R&D Center

VectorBuilder and Landau To Establish World’s First Primate Gene Therapy R&D Center
Product News

VectorBuilder and Landau To Establish World’s First Primate Gene Therapy R&D Center


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "VectorBuilder and Landau To Establish World’s First Primate Gene Therapy R&D Center"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

VectorBuilder Inc. and Landau Biotechnology Co. have signed a strategic partnership that will establish the world’s first primate gene therapy R&D center. The center will build advanced vector screening and optimization platforms to provide unique CRO services to the rapidly growing gene and cell therapy industry. VectorBuilder brings world-leading gene delivery technologies to the venture, while Landau will provide NHP model construction expertise using Macaca fascicularis (crab-eating macaque) and Macaca mulatta (rhesus macaque) species. More specifically, the center will combine directed molecular evolution with in vivo screening in NHPs, resulting in the next generation of gene delivery vectors suitable for human clinical applications. In particular, the center will focus on improving the specificity in tissue targeting and expression pattern of vectors, as well as aiming to reduce toxicity and immunogenicity.

“Nonhuman primates share high degrees of similarities with humans in terms of anatomy, genome function, immunity and physiology. They are therefore ideal animal models for screening and optimizing gene therapy vectors,” said VectorBuilder’s Chief Scientist, Dr. Bruce Lahn. “We believe that by working closely with Landau, we will be able to build a leading CRO capable of providing these much-needed services to the gene and cell therapy community.”

Landau’s President Mr. Lei Fan added: “VectorBuilder is a global pioneer in gene delivery, and we are very pleased to be partnering with the company. The launch of this center marks a major milestone in genetic medicine, and we hope that this will enable us to join hands with other leading biopharmaceutical companies around the world to develop the next generation of gene therapy drugs.” 


Advertisement